Karessa starts preclinical studies with Midazolam
With the project K21, Midazolam, Karessa, we see improved treatment possibilities in various important therapy areas.It concerns treatment of seizures in pediatric epilepsy, calming/anxiolytic effects in minor operations and before dental visits. Midazolam is routinely used globally in these indications. The existing products in the market are relatively difficult to use and it may take time before effects is reached. Before visit to the dentist; todays alternatives should be taken in good time before treatment is initiated. Midazolam, Karessa, may give a direct absorption from the oral